IA
CRSP icon

Inspire Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Inspire Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$940K Buy
19,764
+3,392
+21% +$179K 0.08% 206
2025
Q4 		$859K Buy
16,372
+2,513
+18% +$151K 0.08% 182
2025
Q3 		$898K Sell
13,859
-615
-4% -$35.3K 0.09% 182
2025
Q2 		$704K Buy
14,474
+999
+7% +$38.7K 0.07% 217
2025
Q1 		$459K Buy
+13,475
New +$571K 0.05% 278

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Inspire Advisors's CRSP Position: Q1 2026 in Review

Inspire Advisors increased its CRISPR Therapeutics (CRSP) stake by 21% in Q1 2026, buying an estimated $179K and bringing the position to 19,764 shares worth $940K. The position accounts for 0.08% of the portfolio, ranked #206.

Inspire Advisors first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Inspire Advisors held 19,764 shares of CRISPR Therapeutics worth $940K as of Q1 2026.
  • Inspire Advisors bought 3,392 CRISPR Therapeutics shares in Q1 2026, an estimated $179K.
  • CRISPR Therapeutics made up 0.08% of Inspire Advisors's portfolio in Q1 2026, its #206 holding.
  • Inspire Advisors first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Inspire Advisors's 13F filing for Q1 2026, filed 15 May 2026.